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ABSTRACT 
Objective: Losartan potassium is one of the widely prescribed antihypertensive drugs administered orally and its extended-release tablet 
formulations are essentially required for the long-acting effect at reduced dosage frequency. The present research was aimed for the development 
and optimization of an extended-release tablet of losartan potassium, exploring natural gums, i.e., xanthan gum and guar gum as drug release 
modifiers.  
Methods: The tablet formulation was prepared by wet granulation method and the formulation optimization was done by D-optimal mixture design 
using Design Expert® software. The independent variables studied were xanthan gum (X1), guar gum (X2) and lactose (X3) taking various 
combinations of the total amount of gum and ratio of xanthan gum to guar gum under the given constraint range. The dependent (response) 
variables studied were % drug release in 1h (Y1), 4h (Y2), 7h (Y3) and 10h (Y4). The developed tablets were evaluated for physical properties, i.e., 
hardness, friability, weight variation as well as the in vitro drug release profiles. For optimization studies, the polynomial equations and response 
surface plots were generated and the optimized formulation was selected on the basis of maximum desirability value.  
Results: The developed tablet formulation was found to possess all physical properties within the desired range and showed sustained release 
profile with ~80% drug release in 10 h duration. The model fitting studies demonstrated best fit in the zero-order model and the slope value of 
Korsmeyer–Peppas plot was ˃0.89, suggesting case II transport as a drug release mechanism. 
Conclusion: The findings suggested that natural gums-based matrix tablets of losartan could be successfully developed and natural gums can be 
explored as platform technology as release retardants and in the development of sustained-release matrix tablets of other drugs. 
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INTRODUCTION 
Losartan is an angiotensin II receptor antagonist used for the 
treatment of hypertension and diabetic nephropathy by selectively 
blocking the binding of angiotensin II to the AT1 receptor [1-4]. The 
systemic bioavailability of losartan is ~33% showing peak 
concentration of losartan and its active metabolite in 1 h and 3-4 h, 
respectively. The terminal half-life of losartan is about 2 h and of the 
metabolite is about 6-9 h [1-6]. Dosage regimens of losartan are 
typically 25 mg to 100 mg either once or twice daily. Twice-daily 
dosing at 50-100 mg/day gives consistently larger trough responses 
than once-daily dosing at the same total dose [2]. Hence, there was an 
obvious need of extended-release tablet formulation of losartan in 
order to get a uniform effect over the entire period of 24 h and to 
accomplish patient compliance by eliminating the need of frequent 
drug administration for effective management of hypertension. 
However, the development of sustained-release and gastroretentive 
dosage form of losartan has been tried and reported for the same 
purpose [7, 8]. 
Hydrophilic matrices are the most commonly used extended-
release oral solid dosage forms because of their ability to provide 
desired drug release profiles for a wide range of drugs, robust 
formulation, cost-effective manufacturing and broad regulatory 
acceptance of the polymers [9-11]. Gums are a type of hydrophilic 
matrices used for obtaining extended-release profile [12]. Xanthan 
gum is an extracellular polysaccharide secreted by the micro-
organism Xanthomonas campestris and consists of D-glucose and 
D-mannose as the dominant hexose units, along with D-glucuronic 
acid [13]. Xanthan gum has high drug retarding ability as 
compared to widely used polymer hydroxypropyl methylcellulose 
[14]. The drug release from xanthan gum matrices follows a zero-
order model that conforms to case–II diffusion [15, 16]. Guar Gum 
is another gum obtained from the ground endosperms of seeds of 
Cyamopsis tetragonolobus (Linn.) [17]. It consists mainly of a high 
molecular weight hydrocolloidal polysaccharide, composed of 
galactan and mannan units combined through glycosidic linkages 
[18]. Recently, the potential of guar gum as an inexpensive and 
flexible carrier for oral extended-release tablet of diltiazem have 
been reported [19]. Combination of xanthan gum and guar gum 
was recently explored for the formulation of matrix tablets for oral 
controlled delivery of dipyridamole where the ratio of xanthan to 
gaur gum had equal or dominant role as controlling factor on the 
kinetics of drug release compared to content of polymer blends 
[20].  
The computer-aided formulation optimization has been successfully 
employed in the development of many extended-release products of 
various drugs where the commonly selected independent variables 
are quantities of polymers or release modifiers, while the optimized 
responses invariably were in vitro dissolution profile [21-23]. Mixture 
designs have been widely reported for formulation optimization 
consisting of multiple excipients, where the characteristics of the 
finished product usually do not depend on the quantity of each 
substance but on their proportions. The sum total of the proportions 
of all the excipients is unity, and none of the fractions can be negative, 
therefore, the levels of different components can be varied with the 
restriction that the sum total should not exceed one. In a three-
component mixture, only two-factor levels can be independently 
varied and the remaining factor level is chosen to complete the sum to 
unity [24]. 
In the present investigation, it was proposed to develop the 
extended-release tablet formulation of losartan using xanthan gum 
and guar gum as release controlling natural gums and formulation 
optimization using D-optimal mixture design to achieve the 
desired drug release profile by appropriate contents of natural 
gums. 
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MATERIALS AND METHODS 
Materials 
Losartan potassium was received as a gift sample from Zydus Cadila, 
Ahmedabad (India). Xanthan gum (Xantural® 75) and 
polyvinylpyrrolidone K30 (Kollidon®30) were received as a gift 
sample from Signet Chemical Corporation Pvt. Ltd. Guar gum and 
Lactose monohydrate were procured from Altrafine Gums, 
Ahmedabad (India) and SD Fine-Chem Ltd., Mumbai, (India), 
respectively. All other ingredients used were of analytical grade and 
procured from SD Fine-Chem Ltd., Mumbai (India). 
Preparation of extended-release tablets 
The Losartan extended-release tablets (100 mg) were prepared by wet 
granulation method. The weighed quantity of losartan, xanthan gum, 
guar gum and lactose monohydrate were sifted through a 60-mesh 
sieve. The ingredients were mixed by the geometric dilution 
technique. After blending, granulation was done using a sufficient 
quantity of 5% polyvinylpyrrolidone solution prepared in isopropyl 
alcohol. The wet mass was first passed through a 12-mesh sieve and 
then granules were dried in an oven at 40 °C for 90 min. Then the 
granules were passed through a 25-mesh sieve. Finally the granules 
were lubricated with 1% magnesium stearate, 1% talc and 1% aerosil 
by blending for 3 min. The granulation blend of the extended release 
tablet was compressed into tablets by using 10 mm circular die and 
punches on a rotary tablet compression machine (Karnavati). 
Optimization study using DoE (Design of experiments) 
The formulation optimization was done by D-optimal mixture design 
using Design-Expert software, selecting three independent and four 
dependent variables. The amount of xanthan gum (A), guar gum (B) 
and lactose (C) were selected as the independent variables along 
with the constraints imposed on the sum total of all independent 
variables, on the total amount of gum and on the ratio of the gums. 
The response variables selected were percent release at 1 h (Y1), 4 h 
(Y2), 7 h (Y3) and 10 h (Y4). The independent variables along with the 
constraints and dependent variables, along with the criteria set for 
numerical optimization, are shown in table 1. 
  
Table 1: Variables in D-optimal mixture design for losartan 100 mg tablet formulation 
Independent variable Lower limit (mg) Upper limit (mg) 
A: Xanthan Gum (X1) 1.950 16.250 
B: Guar Gum (X2) 4.875 26.0 
C: Lactose (X3) 179.75 202.5 
Constraints Set for the independent variables 
9.75 ≤ Xanthan Gum+Guar Gum ≤ 32.5 
0.25 ≤ Xanthan Gum/Guar Gum ≤ 1 
Xanthan Gum+Guar Gum+Lactose = 212.250 
Dependent variables with their criteria for optimization 
Percent release in 1 h (Y1) 10-12 
Percent release in 4 h (Y2) 38-40 
Percent release in 7 h (Y3) 62-64 
 Percent release in 10 h (Y4) 80-84 
 
As suggested by the optimization software, the formulations of 
sixteen batches were prepared and their respective effects (i.e., 
response) were determined. The values of factors (independent 
variable) for sixteen batches as suggested are tabulated in table 2. 
 
Table 2: Formulation factors (independent variables) of optimization batches 
Formulation code A: xanthan gum (X1) mg B: guargum (X2) mg C: lactose (X3) mg 
LOT-1 11.375 21.125 179.750 
LOT-2 6.134 9.303 196.813 
LOT-3 11.822 14.991 185.438 
LOT-4 6.947 19.866 185.438 
LOT-5 7.394 13.731 191.125 
LOT-6 1.950 7.800 202.500 
LOT-7 4.875 4.875 202.500 
LOT-8 7.394 13.731 191.125 
LOT-9 6.500 26.000 179.750 
LOT-10 10.563 10.563 191.125 
LOT-11 7.394 13.731 191.125 
LOT-12 7.394 13.731 191.125 
LOT-13 6.500 26.000 179.750 
LOT-14 7.394 13.731 191.125 
LOT-15 16.250 16.250 179.750 
LOT-16 4.225 16.900 191.125 
 
Evaluation of the developed tablets 
Tablets were evaluated for the hardness using digital hardness 
tester (Erweka), friability using Roche friabilator (Electrolab) and 
weight variation using electronic balance (Shimadzu). The drug 
content of the tablets was also determined in methanol using Waters 
HPLC system. The column used was octadecyl silane chemically 
bonded to silica microparticles (3 to 10 µm) and the mobile phase 
was 0.1% phosphoric acid: acetonitrile (3:2). The flow rate was kept 
at 1 ml/min and the injection volume was 20μl [25, 26]. 
In vitro drug release study of optimization batches 
Drug release from extended release tablet was determined by using 
dissolution test (USP Type II) apparatus (Electrolab). The 
dissolution study for first two hours was carried out in hydrochloric 
acid buffer pH 1.2 and then after two hours pH 1.2 buffer was 
replaced by pH 6.8 phosphate buffer. Tablets were placed in the 900 
ml of dissolution media and the rotation of the paddle was fixed at 
50 rpm. 10 ml aliquots of dissolution media were withdrawn at 
suitable time intervals and replaced with same volume of fresh 
dissolution media after each withdrawal. Aliquots collected were 
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diluted if required, filtered through Whatman grade filter 41 and 
then the absorbance of the samples was measured in the first 
derivative UV spectra at 234 nm using UV spectrophotometer 
(Shimadzu® UV-1700). The cumulative % drug release was 
calculated for all the batches. 
Prediction of the optimum formulation 
In order to obtain the optimized formulation, the numerical 
optimization technique was used and on the basis of the criteria set 
for dependent variables and the responses of the optimization 
batches the software gave three formulations with desirability close 
to 1. The formulation with maximum desirability was selected as the 
optimum formulation. For validation three batches of selected 
optimum formula were prepared. The tablets were then evaluated 
for weight variation, friability, hardness, drug content, swelling 
index and in vitro release profile. The comparison of the responses 
of the optimized batch suggested by the software with the responses 
of the validation batches was done. 
Model fitting of the drug release data 
The drug release data of the three validation batches was fitted into 
various mathematical models and the regression coefficients were 
determined. The slope of the Korsmeyer Peppas model was also 
determined in order to determine the possible release mechanism 
[27-29]. 
Determination of swelling index 
Tablets from each batch were soaked individually in 50 ml of pH 1.2 
hydrochloric acid buffer for first two hours followed by pH 6.8 
phosphate buffer for next 8 h. Then after the intervals of 1, 2, 3, 4, 5, 6, 7, 
8, 9 and 10 h the tablets were removed and the excess media on their 
surfaces was carefully absorbed using a tissue paper. The percent 
increase in the weight of the original tablet was calculated (swelling 





Where Wt is tablet weight at various time intervals and W0 is initial 
weight of tablet [30]. 
RESULTS AND DISCUSSION 
Observations of optimization studies 
The hardness of various tablet formulation batches prepared in 
optimization studies (LOT-1 to LOT-16) was found to be 6 to 8 
kg/cm2 and friability of these respective tablet batches ranged from 
0.57% and 0.89% (average 0.68%). The tablet weight of these 
optimization batches varied between 312.17 and 332.16 mg 
(average 322.96 mg) and the drug content was found between 
96.56% and 102.14% (average 98.87%). The % cumulative drug 
release of the optimization batches was also studied over the period 
of 10 h and was found in the range of 68.25% to 96.72%. The 
detailed data of % cumulative drug release is shown in table 3. 
 
Table 3: Observed response variables of optimization batches 
Formulation code % Drug release at the different time interval 
1 h (Y1) 4 h (Y2) 7 h (Y3) 10 h (Y4) 
LOT-1 8.12 30.14 52.68 70.24 
LOT-2 12.23 48.13 79.32 96.72 
LOT-3 8.56 33.19 59.65 79.18 
LOT-4 8.99 37.23 62.28 82.05 
LOT-5 10.14 39.94 64.23 84.95 
LOT-6 13.68 62.14 96.98 93.79 
LOT-7 12.94 52.20 94.26 94.99 
LOT-8 9.85 40.56 63.64 82.67 
LOT-9 8.41 30.25 53.92 71.82 
LOT-10 9.13 36.78 61.14 81.18 
LOT-11 9.99 40.19 65.11 85.42 
LOT-12 10.65 37.96 64.05 83.29 
LOT-13 8.05 28.19 54.33 72.83 
LOT-14 10.16 41.23 63.19 83.27 
LOT-15 7.39 28.88 51.75 68.25 
LOT-16 11.01 40.1 65.12 85.36 
 
Response surface analysis for various responses 
The design was evaluated by a Scheffe’s quadratic model. The 
equation representing the model is given below. 
Y= β1 X1+β2 X2+β3 X3+β12 X1 X2+β13 X1 X3+β23 X2 X3 
Where Y is the measured response associated with each factor level 
combination, β1, β2 and β3 are coefficients of the factors and β12, β13 
and β23 are coefficients of the interaction terms of factors. The table 
3 shows the observed responses of various optimization batches. 
The drug release in 1 h ranged from 7.39% to 13.68%, release in 4 h 
ranged from 28.19% to 62.14%, release in 7 h from 51.75% to 
96.98% and release in 10 h ranged from 68.25% to 96.72%.  
All the responses were fitted into various models i.e., first order, 
second order, quadratic and cubic models and the model with 
highest regression coefficient was selected for the responses. On 
the basis of R2value amongst the responses, release in 1 h and 10 
h followed linear model and release in 4 h and 7 h followed 
quadratic model. In case of release in 4 h, only linear terms of 
quadratic polynomial equation were found to be significant and 
in case of release in 7 h linear terms along with β23 were found to 
be significant. Therefore model reduction was done in case of 
release in 4 h and release in 7 h to improve the model. The 
coefficients of polynomial equations generated using software 
and the respective R2values for various responses are listed in 
table 4. 
  
Table 4: Polynomial coefficient values for response variables 
Coefficient code Polynomial coefficient values for response variables 
Y1 Y2 Y3 Y4 
β1 -0.25888 -8.24695 -10.49607 -0.83574 
β2 -0.12099 -3.51762 -8.93956 -0.48418 
β3 +0.072865 +0.37128 +0.64940 +0.50735 
β23 - - -0.061085 - 
R2 0.9515 0.9758 0.9810 0.9187 
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In case of polynomial equation the positive value suggest that the 
increase in factor favours the response while the negative value suggests 
an inverse relationship between the factor and response. The presence 
of more than one-factor term in polynomial equation suggests the 
presence of interaction and quadratic effects. This also means that the 
relationship between response and factor is not linear. The effect of 
factors and their interactions on the response variables can be analyzed 
in a better way with the help of two-component mix graphs, contour 
plots and the response surface plots. The two component mix graphs are 










Fig. 1: Two component mix graph showing the effect of xanthan gum and guar gum on (a) % drug release in 1 h (b) % drug release in 4 h 










Fig. 2: Response surface plot showing the effect of xanthan gum, guar gum and lactose on (a) % drug release in 1 h (b) % drug release in 4 
h (c) % drug release in 7 h (d) % drug release in 10 h 
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These plots clearly show the linear relationship between factors and 
release in 1 h and release in 10 h and non-linear relationship between 
factors and release in 4 h and 7 h. The two-component mix graph and 
response surface plot showed a decreasing trend in the value of 
percent drug release in 1 h, 4 h, 7 h and 10 h with an increase in the 
amount of xanthan gum and guar gum and an increasing trend with an 
increase in the amount of lactose. Since effect of xanthan gum is more 
prominent than guar gum and lactose, therefore, on replacing xanthan 
gum by guar gum (keeping lactose constant), the release increases.  
Selection and validation of predicted optimum formulation 
The numerical optimization was performed according to the criteria 
set for the responses, as shown in table 1. The software suggested 
three solutions out of which the solution with maximum desirability 
was selected. The selected formulation had a desirability value equal 
to 0.923 and consisted of 9.242 mg of xanthan gum, 11.740 mg of 
guar gum and 191.27 mg of lactose. Three batches of the optimum 
formulation were prepared and were evaluated for various physical 
parameters and the set responses. The average hardness, friability, 
tablet weight, and drug content of tablet formulations of optimized 
validation batches were found to be 6 kg/cm2, 0.63 %, 323.18 mg, 
and 99.17%, respectively. Thus all the physical parameters of the 
optimized validation batches were found to be practically within 
control. The comparison of the responses, i.e., % drug release of the 
optimized batch suggested by the software with the responses of the 
validation batches, is shown in table 5. 
  
Table 5: Responses of the validation batches 
Response Predicted by software Observed in optimized formulation batches 
LT-1 LT-2 LT-3 
% drug release in 1 h (Y1) 10.12 9.46 10.23 9.88 
% drug release in 4 h (Y2) 38.0 38.75 37.83 38.05 
% drug release in 7 h (Y3) 64.0 63.54 64.72 63.19 
% drug release in 10 h (Y4) 83.63 83.51 84.34 84.92 
 
Comparison of the observed and software predicted responses 
showed a good correlation between the observed and predicted 
values. The drug release profile of optimized validation batches is 
shown in fig. 3. 
 
 
Fig. 3: Drug release profile of the optimized validation batches of losartan tablets 
 
Model fitting of the drug release data 
The regression coefficients for various models along with the 
slope of Korsmeyer–Peppas model is shown in table 6. The 
regression coefficients for various plots of all the validation 
batches suggested that the release data showed best fit in zero-
order model. In the Korsmeyer-Peppas equation the value of 
slope for all three batches was found to be above 0.89 which 
suggests that case-II transport is the mechanism of drug release. 
Case II transport follows zero order release kinetics. Thus, 
according to the Korsmeyer-Peppas equation also the release 
data follows zero-order kinetics. 
 
Table 6: Model fitting of drug release data 
Validation 
batches 
Regression coefficients of various models Slope of korsmeyer peppas 
log (m0-m) = log K+n log t First order ln m = kt Higuchi m0-m = kt1/2 Zero order m0-m = kt 
LT-1 0.9773 0.9589 0.9918 0.9087  
LT-2 0.9746 0.9509 0.9931 0.9519 
LT-3 0.9662 0.9573 0.9917 0.8969 
 
Swelling index of an optimized batch of tablets 
The variation of swelling index of optimized tablet batches is 
shown in fig. 4. The tablets showed smaller swelling index in the 
first two hours because xanthan gum swells to a lesser extent in 
the acidic media and guar gum, being highly swellable polymer 
allows faster penetration of dissolution medium, which is 
responsible for the release of drug in the first two hours. The 
swelling index was found to be higher in the later hours when 
media was changed to pH 6.8. In pH 6.8 buffer, xanthan gum shows 
prominent swelling along with the guar gum leading to sustained 
release throughout the period of next 6 h. This swelling accounts 
for the drug released in 4 h and 7 h. Thereafter the swelling index 
reduced because the increase in weight was compensated by 
erosion. The tablet starts eroding after the period of 8 h and this 
probably accounts for the release of the drug in the last two hours. 
The photographs of the swelling study of the optimized 
formulation are shown in fig. 5. 
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Fig. 5: Swelling of the tablets at different time intervals (a) Top view (b) Side view 
 
The high swelling capacity of xanthan gum helped in sustaining 
the drug release in later hours. Though the xanthan gum and guar 
gum individually have already been investigated earlier in matrix 
tablet formulation for sustained drug release [31], in the present 
work combination of these two gums was explored for sustained 
release of losartan potassium from matrix tablet as both the gums 
had their own effect on release kinetics. Resultantly, the 
combination of gums showed desired sustained drug release 
profile. 
CONCLUSION 
The extended-release tablet formulation of losartan was successfully 
prepared using xanthan gum and guar gum and the drug release 
profile of losartan from the tablet was optimized using a D-optimal 
mixture design. The polynomial equations and response surface 
plots helped in understanding the effect of gums on the drug release 
profile. The validation of the optimization methodology was done by 
formulating three batches and determining their responses. The 
model fitting of the release profile suggested that the release profile 
showed the best fit in the zero-order model, and Korsmeyer–Peppas 
plot suggested case-II transport as the probable release mechanism 
of losartan. According to the swelling study, the desired release 
profile was the result of the swelling and erosion process. Thus, the 
combination of natural gums like xanthan gum and guar gum can be 
used in order to obtain the desired drug release profile and the 
optimization of these polymers to obtain the desired drug release 
profile can be successfully done by optimization techniques. 
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